NFKB1 and chronic myelomonocytic leukemia: Notably, the treatment of chronic myelomonocytic leukemia (CMML) patients with hydroxyurea (HU) activates the NF-κB and FOXO1 pathways in proliferating cells, revealing the activation of this pathway in vivo.